The more than two million Canadians who received the AstraZeneca-Oxford COVID-19 vaccine made the right choice, health experts say, despite some provinces pausing its rollout over concerns about the risk of rare blood clots.
The more than two million Canadians who received the AstraZeneca-Oxford COVID-19 vaccine made the right choice, health experts say, despite some provinces pausing its rollout over concerns about the risk of rare blood clots.